公开(公告)号：US08877967B2

公开(公告)日：2014-11-04

申请号：US13786142

申请日：2013-03-05

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary Lynn Trawick

IPC分类号： C07C337/08

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

摘要翻译： 本发明涉及式I化合物和使用这些化合物治疗组织蛋白酶，特别是组织蛋白酶K或组织蛋白酶L的调节将在治疗上有用的条件的方法。

公开(公告)号：USRE45907E1

公开(公告)日：2016-03-01

申请号：US14180238

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： A01N57/00 ,  C07C43/23 ,  C07C45/63 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07F9/12 ,  C07C237/04 ,  C07C47/575

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

公开(公告)号：US20130296605A1

公开(公告)日：2013-11-07

申请号：US13786142

申请日：2013-03-05

申请人： OXIGENE, INC. ,  BAYLOR UNIVERSITY

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

公开(公告)号：US20150141349A1

公开(公告)日：2015-05-21

申请号：US14406725

申请日：2013-06-21

申请人： Angiogene Pharmaceuticals Ltd. ,  OXIGENE, Inc.

发明人： Peter David Davis ,  David J. Chaplin

IPC分类号： A61K31/661 ,  A61K38/12

CPC分类号： A61K31/661 ,  A61K38/12 ,  A61K38/31 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to methods and compositions for treating carcinoid syndrome and other adverse symptoms associated with tumor-producing neuroendocrine tumors, said methods comprising administering a therapeutically effective amount of a vascular disrupting agent, or a pharmaceutically acceptable salt thereof, to a subject having a hormone producing neuroendocrine tumor. In preferred implementations, the vascular disrupting agent is combretastatin A-4 phosphate, combretastatin A-1 diphosphate, or a pharmaceutical acceptable salt thereof.

摘要翻译： 本发明涉及用于治疗类癌综合征和与产生肿瘤的神经内分泌肿瘤相关的其它不良症状的方法和组合物，所述方法包括向具有激素的受试者施用治疗有效量的血管破坏剂或其药学上可接受的盐 产生神经内分泌肿瘤。 在优选的实施方案中，血管破坏剂是考布他汀A-4磷酸盐，考布他汀A-1二磷酸盐或其药学上可接受的盐。

公开(公告)号：US20150031915A1

公开(公告)日：2015-01-29

申请号：US14505165

申请日：2014-10-02

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08 ,  C07C49/786

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

摘要翻译： 本发明涉及式I化合物和使用这些化合物治疗组织蛋白酶，特别是组织蛋白酶K或组织蛋白酶L的调节将在治疗上有用的条件的方法。

公开(公告)号：US09458103B2

公开(公告)日：2016-10-04

申请号：US14505165

申请日：2014-10-02

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08 ,  C07C49/786

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

公开(公告)号：USRE45720E1

公开(公告)日：2015-10-06

申请号：US14180209

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： C07C207/00 ,  C07C207/04 ,  C07C205/37 ,  C07C205/00 ,  C07C217/00 ,  C07C237/00 ,  C07C217/84 ,  C07C237/04 ,  C07C43/00 ,  C07C45/63 ,  C07C43/23 ,  C07F9/00 ,  C07C9/12 ,  C07C47/575 ,  C07F9/12

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.